FDA Grants Breakthrough Therapy Designation to VERTANICAL's VER-01, a First-in-Class Non-Opioid Investigational Treatment for Chronic Low Back Pain

Contributed by: PR Newswire

Tags

Vertanical-FDA

More Like This

PR Newswire associated0

VERTANICAL Announces Positive Results From the VER-01 Phase 3 Program for the Treatment of Chronic Low Back Pain (CLBP)

Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain

JOURNAVX bottle and tablet (Photo: Business Wire)

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

PR Newswire associated0

VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

GRÜNENTHAL'S PROPRIETARY NAV 1.8 INHIBITOR ENTERS CLINICAL DEVELOPMENT

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain